+ cell-derived dendritic cells (DC) will provide a significant advancement towards the development of immunotherapy protocols for cancer, autoimmune disorders and infectious diseases.
Introduction
Advancements in the ability to expand and differentiate DC in vitro from CD34
+ hematopoietic progenitor cells have increased the interest in these cells for clinical immunotherapy protocols. DC are the most potent antigen-presenting cell type for priming of both naive and resting T lymphocytes. [1] [2] [3] [4] [5] [6] Therefore, DC are attractive targets for use in vaccination or therapeutic protocols to prevent or treat a variety of infectious diseases, autoimmune disorders and cancer. DC pulsed with antigen have been used to elicit protective immunity against transplanted tumors in murine models. [7] [8] [9] [10] In addition, this approach has been used successfully in both humans and in murine models to reduce or eradicate established tumors. 8, [11] [12] [13] These studies have provided valuable information that highlights the potential usefulness of DC in immunotherapy.
The most challenging aspect in the development of a successful immunotherapy protocol is the introduction and efficient processing/presentation of the desired antigen. To elicit an appropriate immune response, foreign antigenic peptides must be presented by major histocompatibility complex (MHC) molecules. A variety of methods has been developed to introduce foreign antigens into DC in vitro. They include: (1) incubation with synthetic peptides, purified proteins, whole virus, or tumor extracts; (2) transient transfection of mRNA or plasmid DNA encoding foreign proteins; and (3) direct genetic modification of DC via virus-based gene transfer vehicles. The most commonly used viral-vectors for this approach include adenovirus-, murine leukemia virus (MLV)-, and lentivirus-based vectors. 1, 2, [14] [15] [16] [17] [18] [19] [20] Among these vector systems, the MLV-and HIV-based vectors show great promise for the genetic modification of DC because of their ability to transduce DC progenitors and stably integrate into the genome of the host. Integration, at least in principle, allows for long-term expression of the transgene and efficient MHC-mediated presentation of antigenic peptides. Both MLV-and HIV-based gene transfer systems have been used to transduce CD34 + hematopoietic progenitors that were subsequently differentiated into mature DC capable of stimulating allogeneic T lymphocytes.
marked cells in the presence of the antifolate drug trimetrexate (TMTX). Both MLV-based and HIV-based vectors efficiently transduced cytokine mobilized human peripheral blood CD34 + cells. However, in vitro expansion and differentiation in the presence of GM-CSF, TNF-␣, Flt-3L, SCF and IL-4 resulted in a reduction in the percentage of DC expressing the transgene. Selection with TMTX during differentiation increased the percentage of marked DC, resulting in up to 79% (MLV vector) and up to 94% (lentivirus-vector) transduced cells expressing EGFP without loss of DC phenotype. Thus, MLV-based vectors and in vitro selection of transduced human DC show great promise for immunotherapy

CD34
+ progenitor cells using both types of transfer vectors.
A commonly used approach to increase the overall representation of transduced cells in a mixed population of transduced and untransduced cells is the use of dominant selection strategies. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Dominant selectable markers include naturally occurring human drug resistance genes such as MDR1, DHFR L22Y or DNA alkyltransferases. 22, 23, 25, 26, [31] [32] [33] [34] This approach requires the use of a vector encoding both the gene of interest and the dominant selectable marker. Following transduction, mixed populations of transduced and non-transduced cells are placed under selective pressure where transduced cells have a direct proliferative advantage over non-transduced cells. Thus the overall representation of transduced cells expressing the selectable marker gene can be increased significantly.
We have recently described the dominant selection of primary human CD34
+ progenitor cells in vitro using a bicistronic HIV-based vector expressing EGFP and DHFR L22Y . 35 This vector efficiently transduced human cytokine mobilized peripheral blood (MPB), umbilical cord blood (CB) and bone marrow (BM) CD34
+ cells and expressed both EGFP and DHFR L22Y . 35, 36 Using this selection scheme we have reposted up to 10-fold enrichments of transduced cells. In this report, we compare the transduction of MPB-and CB-derived human CD34
+ progenitor cells via a HIV-based vector and a MLV-based vector. In addition, we report the efficient in vitro enrichment of CD34 + cell-derived DC expressing EGFP and DHFR L22Y following treatment with the antifolate drug trimetrexate (TMTX). Our results show that both types of vectors efficiently transduce CD34 + progenitor cells that can differentiate into functional DC.
Results
Efficient transduction of human CD34 + progenitor cells via MLV-and lentivirus-based vectors
We set out to compare the transduction efficiency of dendritic cell (DC)-progenitors by lentivirus (HIV)-and MLV-based vectors. For this study, cytokine mobilized peripheral blood CD34 + cells were used since they represent a clinically relevant target. In addition, we also used cord blood (CB)-derived CD34 + cells since they have been used by numerous investigators as a readily available source of DC progenitor cells. For the MLV-based vector we used an RD114 pseudotype because of its high transduction efficiency into pre-stimulated CD34 + cells. For transductions with the lentivirus-vector, concentrated vector was added at 0, 24 and 48 h after CD34
+ cell isolation to cells plated on Retronectin-coated wells. For transduction with the MLV(RD114)-vector, CD34
+ cells were prestimulated with cytokines and serum for 48 h before transduction using Retronectin-coated plates preloaded with vector particles essentially as previously described. 36 After transduction, CD34 + cells were maintained in medium containing GM-CSF, TNF-␣, Flt-3L, SCF, and IL-4 to allow differentiation into mature DC. Samples were first analyzed for EGFP expression 5 days after isolation to determine initial transduction efficiency into CD34
+ cells and then on day 14 to assess transgene expression in DC. On day 5, 53% of the cells transduced with the MLV(RD114)-based vector MGirL22Y expressed EGFP. Also on day 5, 61% of the cells transduced with the lentivirus-based vector RtatpEGID expressed EGFP (Figure 1 ). These data show that under our experimental conditions the MLV(RD114) vectors transduced MPB CD34 + cells with a comparable efficiency to the HIVbased vector. However, whichever vector was used, a decrease in the percentage and intensity of the EGFP + cells was noted after 14 days in culture (down to an average of 32% and 38% for the MLV-and lentivirus-vector transduced cells, respectively). This decrease was observed regardless of whether the CD34 + cells were obtained from MPB or CB ( Figure 1 and Table 1 ).
Differentiation of retrovirus and lentivirus transduced CD34
+ cells into DC To determine whether transduction of CD34 + cells via MLV(RD114)-based or lentivirus-based vectors alters the ability of CD34
+ progenitor cells to differentiate into antigen presenting cells, the expression levels of surface markers important for DC-T cell interactions were determined by flow cytometry. For these experiments, MPB CD34 + cells were transduced in parallel using the MLV(RD114)-or the lentivirus-based vectors and differentiated for 14 days as indicated above. On day 14, flow cytometric analysis for cell surface expression of HLA-DR (MHC class II), CD80, CD86, as well as CD1a and CD83 were performed. For this analysis, a DC gate was set using the characteristic population of cells with high forward and side scatter that comprised approximately 40% of the total live cells. 2 As shown in Figure 2 , DC 
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CD34
+ source Vector TMTX % EGFP derived from mock, MLV and lentivirus transduced CD34 + progenitor cells expressed high levels of the DC markers CD1a and CD83. In addition, all three DC populations also expressed high levels of HLA-DR and the costimulatory molecules CD80 and CD86. No significant differences were observed in the expression levels of these markers between the control (mock) and either of the two vector-transduced samples. These data show that transduction via MLV-or lentivirus-based vectors does not affect the ability of MPB CD34
+ progenitor cells to differentiate into mature DC with normal surface phenotypes.
Efficient activation of allogeneic CD3 + T lymphocytes by transduced CD34
+ cell derived DC To evaluate the possibility that the transduction protocol might alter the functionality of the transduced DC, mixed lymphocyte reactions (MLRs) were performed. For this purpose, purified allogeneic CD3 + T lymphocytes were co-cultured with graded doses of lentivirus-, MLV-and mock-transduced DC. Each of these populations of DC efficiently stimulated CD3 + T lymphocytes to proliferate ( Figure 3 ). It should be noted that no significant differences were observed in the ability of either of the two vector-transduced or the mock-transduced DC to stimulate T lymphocytes. These data show that transduction of CD34
+ progenitor cells via lentivirus-or MLV-based vectors and their subsequent differentiation into mature DC does not alter their capacity to stimulate T lymphocytes in MLRs.
Gene Therapy
In vitro expansion and dominant selection of MLV-and lentivirus-vector transduced DC
Decreases in the proportion of cells expressing transgenes after in vitro culture and expansion are often observed reducing the fraction of transduced cells. In an effort to increase the overall percentage of marked DC we evaluated the resistance of transduced MPB CD34 + cells expressing both EGFP and DHFR L22Y to the antifolate drug TMTX. 35 TMTX was added to MPB CD34 + progenitor cells 24 h following transduction and selective pressure was maintained throughout differentiation into mature DC. Flow cytometry was used to determine the percentage of marked cells by gating on the characteristic DC population (high FSC/SSC) and analyzing for the expression of CD1a and EGFP ( Figure 4 and Table 1 ). In the absence of selective pressure, 37% of the MLV transduced cells were positive for both EGFP and CD1a. The lentivirus transduced cells were also 37% positive for both EGFP and CD1a. In contrast, after expansion and differentiation in the presence of TMTX, 79% and 94% of the MLV-and lentivirus-transduced cells expressed EGFP and 72% and 75% also expressed CD1a, respectively. These results show a significant overall enrichment of transduced cells and more importantly of transduced DC.
CB-derived CD34 + progenitor cells can be transduced by both lentivirus-and retrovirus-based vectors. [35] [36] [37] Furthermore, lentivirus vector transduced CB CD34
+ progenitor cells can be used to generate genetically modified DC. 2 Since CB CD34 + progenitor cells are a readily available source of DC we also evaluated TMTX selection of CB-derived DC. CB-derived DC precursor cells were transduced with either MLV-or lentivirus-based vectors with similar efficiency (average of 34% and 35% of EGFP expressing cells for MLV and lentivirus vector, respectively). As indicated in Table 1, the percentage of  CD1a + EGFP + cells transduced with the MLV-based vector increased from an average of 32% to 75% after selection in the presence of TMTX. Similarly, the percentage of CD1a + EGFP + cells transduced with the lentivirus-based vector increased from an average of 31% to 81% after selection in the presence of TMTX. These results show that efficient enrichment of transduced cells can be obtained using DHFR L22Y regardless of the source of CD34 + progenitor cells.
Phenotypic analysis of MLV-and lentivirus-transduced DC after TMTX selection
To determine if the processes of transduction and selection altered the cell surface expression of DC markers and other co-stimulatory molecules, a detailed flow cytometric analysis of DC generated from MPB CD34 + cells in the presence or absence of TMTX selection was performed. Cell surface expression levels of CD1a, HLA-DR, CD80, CD83 and CD86 were determined in control (mock) cells and in cells transduced with both types of vectors cultured in the presence or absence of selection. No significant differences in expression levels of any of these markers were observed regardless of which vector was used for transduction or whether the cells were or were not selected ( Table 2) . Consistent with the results obtained using MPB-derived DC, a similar evaluation of CB-derived DC did not show any significant phenotypic changes following TMTX selection (data not shown). It should be noted that untransduced (mock control) cells Gene Therapy die in the presence of TMTX and thus can not be analyzed for expression of cell surface antigens (indicated by ND in Table 2 ). These results demonstrate that differentiation of CD34 + cells into mature DC in the presence of dominant selective pressure effectively increases the percentage of marked cells without altering the levels of important DC markers and co-stimulatory molecules.
Functional analysis of retrovirus-and lentivirustransduced DC after TMTX selection
To determine if the selection protocol altered the functionality of transduced DC, mixed lymphocyte reactions were performed using TMTX selected or control (nonselected) DC derived from MPB or CB. For these experiments, graded doses of selected or unselected DC were co-cultured with allogeneic CD3 + T lymphocytes and pulsed with [ 
lymphocytes. Purified allogeneic CD3 + T lymphocytes were co-cultured with graded doses of retrovirus-transduced DC in MLRs as described in Materials and methods. Thymidine incorporation is expressed as the mean c.p.m. × 10
of triplicate wells (+/− s.e.m.). Data are representative of four independent experiments. (a) MGirL22Y and RtatpEGID-transduced MPB-derived DC. (b) MGirL22Y and RtatpEGID-transduced CB-derived DC.
the different populations of cells tested. Therefore, transduction of MPB or CB-derived CD34 + cells via MLV-or lentivirus-based gene transfer vectors and subsequent differentiation into mature DC in the presence of dominant selective pressure does not alter the capacity of these DC to activate T lymphocytes. These data indicate that dominant selection can be efficiently used to enrich for transduced functional DC. + cells maintained transgene expression during differentiation, as well as their ability to activate CD3 + T lymphocytes. These results demonstrated the potential use of lentivirus-based vectors to generate antigen-specific dendritic cells that could be used in future clinical applications. However, these studies highlighted two remaining challenges. First, since these vectors are based on HIV-1, a known human pathogen, there is a significant degree of apprehension regarding their clinical implementation. Therefore, a direct comparison of HIV-based vectors and potentially safer but equally effective alternatives, such as MLV(RD114)-based vectors was needed. Second, significant reductions in the percentage of cells expressing the transgene were observed after in vitro culture and differentiation into DC lowering the overall representation of transduced DC.
Discussion
MLV-based vectors pseudotyped with amphotropic or gibbon ape leukemia virus envelopes have been extensively used in clinical protocols for gene therapy and cell marking. These vectors have been found to be safe but their efficacy for the transduction of human CD34
+ cells with in vivo repopulation potential has been disappointing. We have recently described the transduction of CD34 + cells via RD114 (feline endogenous virus envelope protein) pseudotyped MLV vectors. 36 In this study, RD114-pseudotyped vectors were more efficient at transducing human CD34
+ cells than equivalent amphotropic pseudotypes. As anticipated, efficient transduction of CD34
+ cells with either of these MLV-based vectors required a pre-stimulation step with cytokines to induce cell cycling. Since transduction of CD34
+ cells for the purpose of producing DC is done in the presence of cytokines and serum, we anticipated that both lentivirusbased and MLV-based vectors would have similar transduction efficiencies under these conditions. Thus we evaluated and compared the usefulness of both vector systems for the production of genetically modified DC. As indicated in the Results section, both vectors effectively transduced CD34 + cells. In addition, CD34 + cells transduced by both vectors could be induced to differentiate into functional DC. Phenotypic and functional analysis showed no significant differences between cells transduced by either vector system. These results indicated that MLV(RD114) vectors are an excellent alternative to lentivirus-based vectors for the generation of DC from CD34 + progenitor cells. However, it is likely that HIV(RD114) vectors will be very efficient at transducing unstimulated non-dividing CD34 + cells for in vivo repopulating experiments.
One interesting observation made while performing the experiments described above was a time-dependent decrease in the proportion of cells expressing transgene regardless of which vector was used or whether the source of DC progenitors was MPB-or CB-derived CD34 + cells. In order to increase the overall representation of transduced cells in our cultures, we evaluated a dominant selection scheme. We chose the DHFR L22Y gene that confers resistance to TMTX because it has been well characterized both in vitro and in vivo. 23, 35 In both the lentivirus and retrovirus vectors, DHFR L22Y was included with EGFP as part of a single bicistronic message. Expression of DHFR L22Y allows for the in vitro selection of transduced cells in the presence of thymidine phosphorylase (TP) treated serum and TMTX. 23, 35, 36 TP-treated serum is needed because early progenitor cells can resist antifolates such as TMTX by utilizing nucleoside salvage pathways to bypass the de novo synthesis block. [40] [41] [42] [43] The inclusion of TMTX in the culture medium during the 2-week DC differentiation and expansion significantly Tables  1 and 2 ). Selection with TMTX was found to be equally effective for both lentivirus-and retrovirus-transduced cells, indicating the potential usefulness of this system to produce highly enriched populations of DC expressing transgenes. It should be noted that the modest fold increases in transgene expressing cells are due to the high levels of initial transduction efficiency into CD34 + progenitor cells. Since our original transduction efficiency was approximately 35%, the maximum enrichment of three-fold could be obtained. However, greater enrichments are possible if lower transduction efficiencies are observed. In fact, our previous results clearly indicate that significantly larger fold increases can be obtained if the initial transduction efficiency is lower. 23, 35, 36 Unlike lentivirus-based vectors, the use of MLV-based vectors pseudotyped with RD114 for the genetic modification of DC progenitor cells should have immediate clinical applications. DC marking with this vector was very efficient and technically simple due to the ease of vector production and the use of a single transduction step using plates pre-coated with vector particles. In vitro selection and expansion of marked DC will be especially useful for the clinical implementation of these vectors because bulk preparations of clinical grade vectors result in significant reductions in titers. In addition, the levels of transduction observed in the clinic with large numbers of cells is routinely less than that observed in the research laboratory. Thus in a clinical setting, in vitro selection of genetically modified DC will allow for the expansion and enrichment of this population without loss of transgene expression or functionality.
In principle, the genetic modification of CD34 + cells via MLV-or lentivirus-based vectors and their subsequent differentiation into mature DC will allow for the stable integration and expression of a transgene in vitro or in vivo. This could be useful for the development of DCbased vaccines or immunotherapeutic approaches against cancer, autoimmune disorders and infectious diseases. Using bicistronic vectors like those described in this manuscript, DC could be genetically modified to express a variety of cytokines in addition to specific antigens. This modification could further stimulate specific compartments of the immune system and allow for new approaches tailored for specific clinical needs. Further evaluation will certainly be needed in order to assess the full potential of this technology. The fact that transduced DC with normal function and phenotype can be efficiently selected in vitro, as reported herein, will provide momentum to the continuing evaluation of genetically modified DC for clinical protocols.
Materials and methods
Vector production and characterization
The lentivirus vectors used in this study were produced by co-transfecting 293T cells with the plasmids pRtatpE-GID, pBH10⌿ − env − , and pLVSV-G. 37 pRtatpEGID is a Tat-dependent vector for high expression of a cassette containing EGFP, an encephalomyocardiatis virus internal ribosomal entry site, and the DHFR L22Y genes. 35 Calcium phosphate precipitates were formed in the presence of 50 l 2.5 mm CaCl 2 and 0.5 ml 2 × HBSP buffer (pH 7.12) (140 mm NaCl, 5 mm KCl, 0.75 mm NaHPO 4 , Gene Therapy 6 mm glucose, 25 mm HEPES). 35 The vector containing supernatant was collected at 48 and 72 h, pooled, passed through a 0.45 m filter, and concentrated once by centrifugation at 100 000 g for 90 min. The viral pellet was resuspended in serum-free medium and stored at −80°C until used. Vector preparations were titered on HeLa cells as previously described. 38 The titers of the concentrated vector preparations used in this study ranged from 8 × 10 7 to 1 × 10 8 infectious units/ml. Concentrated lentivirus vector supernatants were tested for the presence of replication-competent retroviruses using a CD4 + Hut78 cell infection assay as previously described. 37, 38 No replication-competent retroviruses were detected in any of the vector preparations used to the level of detection of our assay (0.2 to 1 replication competent virus particles per 10 6 functional RtatpEGID particles). Murine leukemia virus (MLV)-based vectors pseudotyped with the feline endogenous virus (RD114) envelope protein were derived from the producer cell line FLYRD18/MGirL22Y essentially as previously described. 36 Producer cell conditioned medium was titered on HeLa cells. The titers of the supernatants used in this study were 0.2 to 1 × 10 6 IU/ml.
CD34
+ cell isolation, transduction, and differentiation into dendritic cells CD34 + cells were isolated from umbilical cord blood or from adult leukopheresis preparations harvested following G-CSF mobilization. Mononuclear cells were isolated by Ficoll-Hypaque separation and CD34
+ cells were purified by positive selection using the Miltenyi MACS CD34 + cell isolation kit according to the manufacturer's instructions (Miltenyi Biotech, Auburn, CA, USA). Purified CD34
+ cells were transduced immediately after isolation in DC medium (Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 100 ng/ml human GM-CSF, 2.5 ng/ml human TNF-␣, 50 ng/ml Flt-3L and 2.5 ng/ml SCF (R& D Systems, Minneapolis, MN, USA)). For DHFR L22Y selection experiments, medium was supplemented with 10% FBS pretreated with thymidine phosphorylase (TP) (1 U/ml TP for 2 h at 37°C, Sigma, St Louis, MO, USA) to deplete the thymidine present in serum thus preventing progenitor cells from utilizing nucleoside salvage pathways that interfere with selection. 32, 40, 42 Lentivirus (RtatpEGID) vector transductions were performed on Retronectin (Takara Biomedicals, Japan) coated plates (20 g/cm 2 ) using three consecutive administrations of vector at 0, 24, and 48 h after isolation using a multiplicity of infection (MOI) of 10 infectious units per cell essentially as we have previously described. 38 Murine leukemia virus (MGirL22Y) vector transductions were performed after 48 h pre-stimulation using Retronectincoated plates pre-loaded with retroviral vector particles before the addition of CD34 + cells. Retronectin-coated plates were pre-loaded with vector particles by placing 0.25 ml/cm 2 of producer line conditioned medium in each well, incubating for 30 min at room temperature, washing with IMDM, and adding 2 × 10 5 /cm 2 CD34 + cells. Transduced and mock-transduced CD34 + cells were expanded for 4 days in DC medium. Human IL-4 (10 ng/ml) was added to the DC culture medium and cells were expanded for an additional 10 days (14 days total) before analysis by flow cytometry and mixed lymphocyte reactions (MLR). For selection experiments, 100 nm Neu-trexin (trimetrexate glucuronate, TMTX) (US Bioscience, West Conshohocken, PA, USA) was added to the DC culture medium on day 4 after isolation. Flow cytometric analysis and stimulatory activity in mixed lymphocyte reactions (MLRs) were performed on day 14.
Purification of CD3
+ T lymphocytes Peripheral blood mononuclear cells from normal healthy donors were isolated by Ficoll-Hypaque separation. Human T-cell enrichment columns (R&D Systems Inc., Minneapolis, MN, USA) were used according to the manufacturer's instructions to obtain negatively selected CD3 + T lymphocytes. T-cell purity was assessed by flow cytometry. The purified CD3
+ T lymphocytes were resuspended in RPMI 1640 supplemented with 10% normal human serum.
Mixed lymphocyte reactions DC derived in vitro from purified CD34
+ progenitors were irradiated (3000 rad) using a 137 Cesium source. Graded doses of DC (312 to 10 000) were co-cultured with 1 × 10 5 freshly isolated CD3 + T lymphocytes in 96-well round bottom plates for 6 days at 37°C. The culture medium used in the mixed lymphocyte reactions consisted of RPMI 1640 supplemented with l-glutamine (0.3 mg/ml), penicillin G (200 U/ml), gentamicin (10 g/ml) and 10% normal human serum. To assess DNA synthesis by activated T lymphocytes, cultures were pulsed with 1 Ci/well of [ 3 H]-thymidine (6.7 Ci/mm, New England Nuclear, Boston, MA, USA) for the last 18 h of culture. Cells were harvested on to glass fiber filters using a semiautomatic harvester (Cambridge Technology, Watertown, MA, USA) and thymidine incorporation was assessed by liquid scintillation counting. The results are expressed as the mean of triplicate wells (c.p.m. ± s.e.m.).
Flow cytometry
Samples processed for flow cytometry were stained with one or a combination of the following mouse monoclonal antibodies or similarly labeled isotype controls: anti-CD34 (clone My10), anti-HLA-DR (clone L243), anti-CD3 (clone SK7) (Becton Dickinson, San Jose, CA, USA) and anti-CD1a (clone HI149), anti-CD80 (clone BB1), anti-CD86 (clone B70/B7-2) (Pharmigen, San Diego, CA, USA) and anti-CD83 (clone HB15A) (Immunotech, Marseille, France). Four-color flow cytometry was performed using a FACSCalibur flow cytometer and the data were analyzed using the CellQuest software package (Becton Dickinson). The dendritic cell population was analyzed by gating for their characteristic forward (FSC) and side (SSC) scattered profile as well as staining with CD1a essentially as previously described. 
